KR20150018259A - Composition for skin moisturizing comprising paeonol - Google Patents

Abstract

The present invention provides a composition, especially, a cosmetic composition or a pharmaceutical composition containing paeonol or a pharmaceutically acceptable salt thereof for promoting the differentiation of skin keratin cells, improving skin moisturizing, and/or enhancing skin barriers. The cosmetic composition or the pharmaceutical composition of the present invention has less side effects and thus is safe to human body, and has superior abilities to differentiate skin keratin cells, enhance skin barriers, and promote skin moisturizing.

Description

[0001] Composition for skin moisturizing comprising paeonol [

The present invention relates to a composition, particularly a cosmetic composition or a pharmaceutical composition, for promoting differentiation, keratinization, and skin barrier recovery of keratinocytes. Or a pharmaceutical composition.

Vitamin D (vitamin D) is essential for skeletal growth and maintenance, homeostasis of calcium and phosphorus, and plays an important role in the prevention and treatment of osteoporosis as well as in tissues other than the skeletal system.

There are two mechanisms by which vitamin D acts on cells. First, vitamin D binds to the vitamin D receptor (VDR). Vitamin D receptors are expressed in various cells including keratinocytes. The combination of vitamin D and vitamin D receptors enters the intracellular nucleus and binds to a specific DNA sequence called the vitamin D recognition element (VDRE), which acts as a transcription factor, Lt; / RTI > This causes transcription of genes that primarily affect cell proliferation. The other is to allow the intracellular calcium ions to flow. Vitamin D acts on a series of processes that increase the concentration of calcium ions in the cell, thereby promoting the differentiation of keratinocytes.

The combination of these two mechanisms inhibits the proliferation of target cells and promotes differentiation. In addition to cell proliferation and cell differentiation, vitamin D also has immunomodulatory functions. It inhibits the T cell response to IL-1 and inhibits interleukin-2, interleukin-6, and interferon-γ production, which are important for the immune response. In addition, it promotes inhibition of T cell activation and inhibits the formation of NK (natural killer) cells. These combinations of vitamin D, cell proliferation, cell differentiation, and immunomodulation can explain why Vitamin D and its derivatives are effective in the treatment of psoriasis.

However, these vitamin D and vitamin D derivatives are prohibited raw materials that can not be used in cosmetics, and studies on substances capable of increasing the transcriptional activity of vitamin D receptors, which can be used in cosmetics, have not yet been conducted.

Accordingly, there has been a constant demand for useful active ingredients having an effect related to promotion of keratinocyte differentiation, skin moisturization enhancement, and skin barrier recovery that can be stably used in cosmetics and the like while solving the above-mentioned disadvantages and side effects.

Accordingly, the present invention is to solve the above-mentioned problems, and to provide new useful active ingredients, that is, active ingredients that are safe for human body and promote differentiation of keratinocyte, skin moisturizing enhancement and skin barrier recovery with few side effects .

In other words, a problem to be solved by the present invention is to provide a composition, particularly a cosmetic composition or a pharmaceutical composition, containing the active ingredient with excellent efficacy as an active ingredient.

In order to solve the above problems, the present invention relates to a composition for accelerating the differentiation of keratinocytes, for enhancing skin moisturization, for restoring skin barrier, which comprises phaeonol or a pharmaceutically acceptable salt thereof as an active ingredient, Or a pharmaceutical composition.

That is, the present invention provides a novel use of paeonol or a pharmaceutically acceptable salt thereof for promoting differentiation of keratinocytes, for skin moisturizing enhancement, or for restoring skin barrier.

Furthermore, the present invention provides a method for treating skin, including at least one of skin dryness, atopic symptoms, and contact dermatitis caused by incomplete epidermal differentiation by normally reducing and maintaining differentiation of keratinocytes when applied to skin Prevention and / or ameliorating effects of the present invention.

In addition, the composition of the present invention enhances the water retention ability of the skin by enhancing the skin barrier and improves the flexibility and durability of the skin to smoothly perform the original protective function of the skin, The occurrence of fine wrinkles can be reduced.

The present invention also provides a composition for activating transcription of vitamin D receptors, particularly a cosmetic or pharmaceutical composition, which has an effect similar to that of vitamin D and has improved safety by activating transcription of vitamin D receptor.

The paeonol of the present invention has a chemical formula of C ₉ H ₁₀ O ₃ and a molecular weight of 166.18, which can be represented by the following chemical formula 1.

[Chemical Formula 1]

The paeonol increased cytochrome oxidase and vascular actin in the cerebral cortex and improved behavior in the experimental model of Alzheimer's disease. The antiinflammatory, analgesic and histamine and TNF -α is known to suppress hypersensitivity.

However, there is no known fact that the Paeolol promotes keratinocyte differentiation, skin moisturizing, and / or damaged skin barrier recovery of the skin.

The compound represented by the formula (1) can be isolated from plants containing peanut and the like, but the present invention is not limited to the method for obtaining such a paeonol. The paeonol according to the present invention may be chemically synthesized by a method known in the art, or a commercially available material may be used.

The term "pharmaceutically acceptable salts " of the present invention refers to salts prepared with little or no toxicity or with acids or bases. When the compound of the present invention is relatively acidic, the base addition salts may be obtained by contacting a neutral form of such compound with a sufficient amount of the desired base and an appropriate inert solvent. Pharmaceutically acceptable base addition salts include, but are not limited to, salts formed with sodium, potassium, calcium, ammonium, magnesium or organic amino. Where the compounds of the present invention are relatively basic, acid addition salts can be obtained by contacting neutral forms of such compounds with a sufficient amount of the desired acid and a suitable inert solvent. Pharmaceutically acceptable acid addition salts include those derived from organic acids such as propionic acid, isobutyric acid, oxalic acid, malic acid, malonic acid, benzoic acid, succinic acid, sueric, fumaric acid, mandelic acid, phthalic acid, benzenesulfonic acid, Phosphoric acid, monohydrogencarbonic acid, phosphoric acid, monohydrogenphosphoric acid, dihydrogenphosphoric acid, sulfuric acid, monohydrogensulfuric acid, hydrogen iodide, phosphorous acid, And the like, but are not limited thereto. But are not limited to, salts of amino acids such as arginate and analogs of organic acids such as glucuronic or galactunoric acids.

The paeonol of the present invention may exist in unsolvated form as well as solvated form including form of hydrate, ethanol, and the like. The paeonol of the present invention may exist in crystalline or amorphous form, and all such physical forms are included within the scope of the present invention.

The paeonols of the present invention may also be present in the form of pro-drugs. In particular, prodrugs which can be separated into the paeonol, which is in its active form by esterase or amidase present in the skin, can be used. Specifically, in order to control the hydrophilicity / lipophilicity, the skin absorbency, the solubility and the pharmacokinetics of pahenol, alkyl having 1 to 6 carbon atoms, alkenyl having 1 to 6 carbon atoms, haloalkyl having 1 to 6 carbon atoms, An alkoxyalkyl group having 1 to 6 carbon atoms, an alkoxyalkyl or alkoxyalkoxyalkyl group having 1 to 6 carbon atoms, a phenacyl group, a phenacyl group substituted with an alkyl having 1 to 6 carbon atoms, an alkoxy group having 1 to 6 carbon atoms, Substituents such as a carbonylalkyl group, a cyanoalkyl group having 1 to 6 carbon atoms, and an alkylthioalkyl group having 1 to 6 carbon atoms in each alkyl moiety may be linked to the -OH group of a paernol by an ester bond or an amide bond. Such prodrugs can be made by methods well known in the art, such as those described in BURGER'S MEDICAL CHEMISTRY AND DRUG DISCOVERY, 172-178, 949-982 (Manfred E. Wolffed., 5th ed. .

The inventors of the present invention have repeatedly studied various components and found that paeonol or a pharmaceutically acceptable salt thereof exhibits an excellent skin moisturizing ability as well as an effect of promoting keratinocyte differentiation promotion and skin barrier enhancement Found.

Accordingly, the present invention can provide a cosmetic composition that promotes keratinocyte differentiation, has a skin barrier strengthening effect and / or an excellent skin moisturizing ability.

In addition, the present invention can provide a pharmaceutical composition for accelerating the differentiation of keratinocytes, for strengthening skin barrier, and / or for skin moisturizing, which comprises paeonol as an active ingredient.

The composition of the present invention may contain other ingredients such as a moisturizer, a thickener, a surfactant, a surfactant, a preservative, an antioxidant, a preservative, an antioxidant, an antioxidant, Alcohol, flavor, pH controlling agent, natural extract, and the like, as well as chemical and / or natural ingredients for improving the effect of the present invention.

The composition of the present invention can be manufactured in the form of medicines, functional foods and cosmetics. Such medicaments, functional foods and cosmetics may include pharmaceutically or cosmetically acceptable excipients or additives. The compositions of the present invention may be administered alone or in admixture with any convenient vehicle, excipient, or the like, and such dosage forms may be single-dose or multiple-dose formulations.

The composition of the present invention may be a solid preparation, a semi-solid preparation or a liquid preparation. Solid preparations include, but are not limited to, powders, granules, tablets, capsules, suppositories, and the like. Solid form preparations may include, but are not limited to, excipients, flavoring agents, binders, preservatives, disintegrants, lubricants, fillers, and the like. Examples of the semi-solid preparation include a cream, a lotion, an emulsifier, a liniment, and the like, but the present invention is not limited thereto, and can be produced by adding a suitable colorant, a flavoring agent, a stabilizer, a tackifier, a surfactant, and the like. Examples of the liquid preparation include water, alcohols, solutions such as solutions of propylene glycol, suspensions, emulsions and the like, but not limited thereto, and they can be prepared by adding appropriate coloring agents, flavoring agents, stabilizers, tackifiers and the like.

For example, powders can be prepared by simple mixing of the phahenol or salt thereof of the present invention with an appropriate pharmaceutically acceptable excipient such as lactose, starch, microcrystalline cellulose and the like. The granules may contain the paeonol or its salt of the present invention; Suitable excipients which are pharmaceutically acceptable; And a suitable pharmaceutically acceptable binder such as polyvinylpyrrolidone or hydroxypropylcellulose, followed by wet granulation using a solvent such as water, ethanol or isopropanol or dry granulation using a compressive force . Further, the tablet may be prepared by mixing the above granule with a suitable pharmaceutically acceptable salt such as magnesium stearate and then tableting it using a tablet machine. Also, for example, the external preparation for skin may be a pharmaceutically or cosmetically acceptable suitable substance such as vaseline, stearyl alcohol and the like; A suitable pharmaceutically or cosmetically acceptable surfactant such as polysorbate, sorbitan sesquioleate, and the like; Suitable pharmacologically or cosmetically acceptable moisturizing agents such as glycerin; A suitable pharmaceutically or cosmetically acceptable solvent; And a conventional external preparation for skin preparation in which a flavoring agent, a coloring agent, a stabilizer, a tackifier and the like are homogeneously mixed.

On the other hand, the cosmetic composition containing paeonol of the present invention can be manufactured in various formulations such as cosmetics, lotions, and creams, and can be applied in various forms such as emulsion, cream, and paste, And can be produced by using a conventional cosmetic preparation method.

The cosmetic composition or the pharmaceutical composition of the present invention contains 0.0005 to 5% by weight, and preferably 0.001 to 1% by weight, of the total weight of the composition, of Paeonol or a pharmaceutically acceptable salt thereof.

If less than 0.0005% by weight of the above-mentioned paefnol or its salt is not desired, it is not preferable because it can not sufficiently attain the intended effect of accelerating differentiation of keratinocyte differentiation, skin moisturizing effect and / or skin barrier recovery. It is uneconomical that the effect of the cosmetic composition and the pharmaceutical composition can not be expected to increase remarkably.

In order to achieve the object of promoting keratinocyte differentiation, skin moisturizing effect and / or skin barrier restoration effect according to the present invention, the paeonol of the present invention or a pharmaceutically acceptable salt thereof is administered in an amount of about 0.01 mg / kg to about 10 g / kg may be administered, and a daily dosage of about 0.1 mg / kg to about 1 g / kg is preferred. However, the dosage may vary depending on the route of administration and formulation, the patient's condition (age, sex, weight, etc.), severity of the condition being treated, and the like. For convenience, the total daily dose may be divided as needed and divided into several doses throughout the day.

The composition containing the paeonol of the present invention or a pharmaceutically acceptable salt thereof promotes dermal keratinocyte differentiation.

In addition, it promotes the differentiation of keratinocytes, thereby alleviating or ameliorating skin dryness symptoms, atopic symptoms and contact dermatitis symptoms.

The composition containing the paeonol or its pharmaceutically acceptable salt of the present invention strengthens the skin barrier, increases the flexibility and firmness of the skin, and increases the ability of the skin to retain moisture.

In addition, by activating transcription of the vitamin D receptor, it exerts a similar effect to vitamin D in keratinocytes, and thus it can be used as a safe and excellent cosmetic material.

FIG. 1 is a graph showing the results of measurement of VDR transcription activity by the concentration of paeonol using a reporter gene measurement method.
FIG. 2 is a graph showing the effect of quantitative real time PCR on mRNA expression of paeonol VDR in human keratinocytes. FIG.
FIG. 3 is a graph showing the effect of paitonol on involucrin mRNA expression in keratinocytes derived from human using quantitative real time PCR.
FIG. 4 is a graph showing the effect of quantitative real-time PCR on the expression of mRNA of paeolol Fillaggrin in human keratinocytes.
5 is a table showing primer sequences used in quantitative real time PCR.

Hereinafter, the present invention will be described in more detail with reference to the following examples. However, the embodiments according to the present invention can be modified into various other forms, and the scope of the present invention should not be construed as being limited to the above-described embodiments. The embodiments of the present invention are provided by way of example to facilitate a specific understanding of the present invention.

Paeonol used in the following examples of the present invention was purchased and used from Xian natural field biotechnology Co. Ltd., China.

Example 1 Evaluation of Transcriptional Activation of Vitamin D Receptor (VDR)

HaCaT, a human keratinocyte, was subcultured in Dulbecco's modified Eagle's medium (DMEM; Invitrogen, USA) containing steroid hormone-free fetal bovine serum (5% charcoal stripped FBS). Plasmids were purchased from VDRE reporter (Qiagen, Germany), which was constructed by plasmids and Renilla luciferase, which was made by VDR to express the reporter gene firefly luciferase, Lt; RTI ID = 0.0 > 40: < / RTI > ^Four 5 x 10 HaCaT cells were plated on a 24 well plate and incubated for 18 hours. One gram of the VDRE reporter plasmid gene was transiently transfected using a lipofectamine reagent (Invitrogen, USA) according to the manufacturer's instructions transient transfection). The cells were incubated for 24 hours, washed with phosphate buffered saline (PBS), and then added to the DMEM medium without fetal bovine serum (0.02, 0.2, 2 μg / ml). As the negative control group, the group treated with DMSO used for dissolving the paeonol was used. After culturing for 24 hours, the cells were washed with phosphate buffer solution, and the cells were lysed using a cell lysis buffer. Then, only the supernatant was extracted using a centrifuge to perform luciferase assay, and then Perkin Elmer Victor 3 (USA) (Luminescence) was measured and shown in Table 1 and Fig.

Growth rate (%) = (control-sample treated group) / control x 100 (%)

Name of sample Control group Paeonol
20 / / ml Paeonol
40 / / ml Paeonol
60 / / ml Growth rate    - 74% 98% 124%

As shown in Table 1 and FIG. 1, it can be seen that the paeonol according to the present invention increases the activity of VDR to a significant degree depending on the concentration, indicating high luciferase activity.

<Example 2> Modulation effect of VDR, Involucrin and Fillagrin gene expression

Human keratinocytes were purchased from ATCC (USA). Dermal basal cell media (DBCM, ATCC, USA) was used and keratinocyte growth factor (KGF, ATCC, USA) was used. 2x10 ⁵ cells were plated in 6-well plates and cultured for 18 hours, followed by treatment with 2 μg / ml of paeonol for 48 hours. Cells were harvested and washed with PBS. Total RNA was extracted with RNeasy mini kit (Qiagen, Germany), and 1 μg of RNA was quantitatively analyzed using GeneAmp® RNA PCR kit (Applied Biosystems, USA) reverse transcription). Reverse transcription reactions were performed using Mycycler® PCR instrument (Biorad, USA).

Quantitative real-time PCR was performed using iTaq ™ Fast SYBR® Green Supermix With ROX (Biorad, USA) and gene-specific primers. Real-time PCR was performed using a CFX96 Touch ™ Real-Time PCR Detection System instrument (Biorad, USA). The primer sequences used in the quantitative real time PCR are shown in Table 2. All primers were custom made in Korea. Experimental results obtained by real-time PCR were compared with those of the housekeeping gene Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) using the ΔΔCt method (Livak KJ, Schmittgen TD: Analysis of relative gene expression data using real- Delta Delta C (T)) Method, Methods, 25, 402-408 (2001). In addition, by quantifying the amount of mRNA expression in the experimental group treated with paitonol based on the mRNA expression level of the negative control group as 1.0 2 to 4.

gene Name of the primer Primer sequence SEQ ID NO: VDR VDR-L 5'-CCA GTT CGT GTG AAT GAT GG -3 ' One VDR-R 5'-AGA TTG GAG AAG CTG GAC GA-3 ' 2 Involucrin IVL-L 5'-GAA CAG CAG CAA AAG CAC CT -3 ' 3 IVL-R 5'-CAA ACA CAG GCT GCT CCA -3 ' 4 Fillaggrin FLG-L 5'-AGT GAG CAT TAC CCA GAG GA-3 ' 5 FLG-R 5'-CTG TAT CGC GGT GAG AGGA-3 ' 6 GAPDH GAPDH-L 5'-GGC TCT CCA GAA CAT CAT CC -3 ' 7 GAPDH-R 5'-TTC TAG ACG GCA GGT CAG GT -3 ' 8

As shown in FIGS. 2 to 4, the paeonol according to the present invention promotes differentiation of keratinocytes and increases skin moisturization by inducing VDR transcription activity or increasing expression. It promotes the differentiation of keratinocytes by increasing the expression of involurin, an important marker of keratinocyte differentiation, and promotes the differentiation of keratinocytes, which is a precursor of natural moisturizing factor (NMF) Green (Fillaggrin) gene expression was shown to increase the effect. Thus, it is believed that the paeonol or its pharmaceutically acceptable salt according to the present invention promotes keratinocyte differentiation and increases the ability to retain moisture in the skin. Furthermore, the present invention is believed to be effective for preventing or improving skin dryness symptoms and atopic symptoms caused by incomplete epidermal differentiation of the skin from the above results, enhancing the flexibility and durability of the skin, Which is expected to exert an excellent effect on moisturizing the skin.

&Lt; Example 3 > Reinforcing effect of skin barrier function recovery

Clinical studies were conducted to examine the effect of the composition according to the present invention on restoring skin barrier function. Subjects were selected from 27 healthy adult men and women aged 24 to 48 years (mean age 30.6 years) according to the criteria for selection and exclusion of subjects. Subjects were informed in advance of the test related matters and volunteered to participate The test was conducted under the agreement of participation in the human body test. All human body tests were conducted at constant temperature (22 ± 2 ℃) and humidity (40 ~ 60%). Transepidermal water loss (TEWL) was measured using a Tewameter TM210 (C & K. Germany), and the mean value was used five times for each test site.

The ventral forearm was used for the test and the TEWL was measured before the start of the test and used as the base value before the barrier fracture. 1% SLS solution was prepared by using distilled water, placed in the IQ chamber, and placed on the test site to destroy the skin barrier for 24 hours. After 24 hours, the chamber was removed and the test area was marked with black. The next day, TEWL was measured and used as the barrier disruption value before sample application. The test samples were prepared by dissolving Paeonol in DPG at concentrations of 3, 5, 10, and 20 ㎍ / ml. The sample-untreated site was used as a negative control. Samples were applied to the test site twice in the morning and evening, and TEWL was measured after 1 day, 3 days, 7 days, and 14 days, respectively. The test was performed by the double blind method. Statistical analysis was performed using a paired t-test. The significance level between the sample site and the control site was found to be 5% (p <0.05). Statistical analysis program was performed using Microsoft Excel version 2010 software. In terms of efficacy, there was a statistically significant difference between the site of use and the control site. From the safety standpoint, it was judged to be a sample to help improve the barrier recovery when no adverse reaction was caused by the product during the use period. The barrier recovery rate was calculated according to the following equation.

Barrier recovery rate (%) = [1- (TEWL measurement value after x days of sample use - TEWL measurement value before barrier destruction) / (TEWL measurement value before sample application - TEWL measurement value before barrier destruction) x100

(* p < 0.05, ** P < 0.01) After 1 d After 3 d After 7 d After 14d Untreated site 16.7 ± 10.5 42.2 ± 17.3 62.5 ± 20.4 72.7 ± 12.3 DPG-treated site 18.3 ± 11.9 42.8 ± 15.7 61.3 ± 21.7 74.3 ± 20.3 50 μg / ml paeonol 18.1 ± 12.0 38.9 ± 16.5 63.2 ± 13.5 75.2 ± 11.2 100 μg / ml paeonol 18.7 ± 14.2 39.2 ± 19.3 61.3 ± 19.2 79.6 ± 15.6 150 μg / ml paeonol 21.2 ± 13.2 39.7 ± 15.6 64.9 ± 12.9 84.3 ± 13.7 * 200 μg / ml paeonol 20.3 ± 10.3 39.6 ± 14.5 74.3 + - 11.0 * 87.2 ± 11.2 **

As shown in Table 3, 85.4% (p <0.05) of the 10 μg / ml paeonol after 14 days of application and 75.1% (p <0.05) of 20 μg / ml paeonol after 7 days of application p <0.05). After 14 days of application, the barrier recovery rate was 85.0% (p <0.01), which was statistically significant compared with the untreated control site. No skin adverse events were observed during the sample period. Therefore, it was found that 10 ㎍ / ml pahenol had a skin barrier recovery effect from 14 days after application, and 7 days after application of 20 ㎍ / ml pahenol. Therefore, it is considered that the use of the paeonol of the present invention or a pharmaceutically acceptable salt thereof can effectively restore the damaged skin barrier. Furthermore, from the above results, it can be said that the composition of the present invention restores the damaged skin barrier and smoothly carries out the original protective function of the skin, thereby being effective for skin dryness diseases and also reducing the skin wrinkles caused by skin dryness.

In view of the results of Examples 1 to 4 above, even if paeonol has an effect similar to vitamin D in vitro, it is possible to achieve skin moisturizing effect, skin barrier strengthening effect and / or keratinocyte differentiation effect in vivo Can be confirmed through experiments of the present invention.

&Lt; Preparation Example 1 >

Composition (% by weight) Production Example 1 Paeonol 1.0 Vaseline 2.0 Sesquioleic acid sorbitan 0.8 Polyoxyethylene oleylethyl 1.2 Methyl paraoxybenzoate Suitable amount Propylene glycol 5.0 ethanol 3.2 Carboxyvinyl polymer 18.0 Potassium hydroxide 0.1 Pigment Suitable amount incense Suitable amount Purified water to 100

As shown in Table 4, a nutritional lotion containing paeonol as an active ingredient was prepared by a conventional method.

&Lt; Preparation Example 2 > Preparation of essence

Composition (% by weight) Production Example 2 Paeonol 1.0 glycerin 10.0 Sodium hyaluronate aqueous solution (1%) 5.0 Polyoxyethylene hardened castor oil 1.0 Methyl paraoxybenzoate 0.1 Spices 0.05 Purified water to 100

Essences containing paeonol as an active ingredient were prepared according to a conventional method as shown in Table 5 above.

&Lt; Preparation Example 3 >

Composition (% by weight) Production Example 3 Paeonol 1.0 Stearic acid 15.0 Cetanol 1.0 Potassium hydroxide 0.7 glycerin 5.0 Propylene glycol 3.0 antiseptic Suitable amount incense Suitable amount Purified water to 100

As shown in Table 6, a cream containing paeonol as an active ingredient was prepared by a conventional method.

&Lt; Preparation Example 4 > Preparation of pack

Composition (% by weight) Production Example 4 Paeonol One glycerin 5.0 Propylene glycol 4.0 Polyvinyl alcohol 15.0 ethanol 8.0 Polyoxyethylene oleylethyl 1.0 Methyl paraoxybenzoate 0.2 incense Suitable amount Pigment Suitable amount Purified water to 100

As shown in Table 7, a pack containing paeonol as an active ingredient was prepared according to a conventional method.

Preparation Example 5 Preparation of ointment for external preparation for skin

Composition (% by weight) Production Example 5 Epipredelanol 0.2 Diethyl sebacate 8 Nonsense 5 Polyoxyethylene oleyl ether phosphate 6 Sodium benzoate One vaseline to 100

As shown in Table 8, ointments among external preparations for skin containing paeonol as an active ingredient were prepared according to a conventional method.

Claims (8)

1. A cosmetic composition for accelerating the differentiation of keratinocyte, comprising paeonol or a pharmaceutically acceptable salt thereof as an active ingredient. 1. A cosmetic composition for skin moisturizing comprising phaeonol or a pharmacologically acceptable salt thereof as an active ingredient. 1. A cosmetic composition for skin barrier enhancement comprising as an active ingredient a phaenool or a pharmacologically acceptable salt thereof. 4. The cosmetic composition according to any one of claims 1 to 3, wherein the cosmetic composition comprises 0.001 to 1% by weight, based on the total weight of the composition, of pahenol or a pharmaceutically acceptable salt thereof. A pharmaceutical composition for accelerating the differentiation of keratinocyte, comprising paeonol or a pharmaceutically acceptable salt thereof as an active ingredient. A pharmaceutical composition for moisturizing skin, comprising as an active ingredient a phaainol or a pharmaceutically acceptable salt thereof. A pharmaceutical composition for enhancing skin barrier comprising paeonol or a pharmaceutically acceptable salt thereof as an active ingredient. 8. The pharmaceutical composition according to any one of claims 5 to 7, wherein the pharmaceutical composition is characterized in that the content of the pahenol or a pharmaceutically acceptable salt thereof is 0.001 to 1% by weight based on the total weight of the composition.

Images